Worthington J - Search Results

1

Targeting the p300/CBP Axis in Lethal Prostate Cancer.

Welti J, Sharp A, Brooks N, Yuan W, McNair C, Chand SN, Pal A, Figueiredo I, Riisnaes R, Gurel B, Rekowski J, Bogdan D, West W, Young B, Raja M, Prosser A, Lane J, Thomson S, Worthington J, Onions S, Shannon J, Paoletta S, Brown R, Smyth D, Harbottle GW, Gil VS, Miranda S, Crespo M, Ferreira A, Pereira R, Tunariu N, Carreira S, Neeb AJ, Ning J, Swain A, Taddei D; SU2C/PCF International Prostate Cancer Dream Team; Schiewer MJ, Knudsen KE, Pegg N, de Bono JS. Welti J, et al. Among authors: worthington j. Cancer Discov. 2021 May;11(5):1118-1137. doi: 10.1158/2159-8290.CD-20-0751. Epub 2021 Jan 11. Cancer Discov. 2021. PMID: 33431496 Free PMC article.

2

Attenuating Adaptive VEGF-A and IL8 Signaling Restores Durable Tumor Control in AR Antagonist-Treated Prostate Cancers.

Maxwell PJ, McKechnie M, Armstrong CW, Manley JM, Ong CW, Worthington J, Mills IG, Longley DB, Quigley JP, Zoubeidi A, de Bono JS, Deryugina E, LaBonte MJ, Waugh DJJ. Maxwell PJ, et al. Among authors: worthington j. Mol Cancer Res. 2022 Jun 3;20(6):841-853. doi: 10.1158/1541-7786.MCR-21-0780. Mol Cancer Res. 2022. PMID: 35302608 Free PMC article.

3

Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer.

Wilson C, Scullin P, Worthington J, Seaton A, Maxwell P, O'Rourke D, Johnston PG, McKeown SR, Wilson RH, O'Sullivan JM, Waugh DJ. Wilson C, et al. Among authors: worthington j. Br J Cancer. 2008 Dec 16;99(12):2054-64. doi: 10.1038/sj.bjc.6604804. Epub 2008 Dec 2. Br J Cancer. 2008. PMID: 19050703 Free PMC article.

4

Targeting Hypoxic Prostate Tumors Using the Novel Hypoxia-Activated Prodrug OCT1002 Inhibits Expression of Genes Associated with Malignant Progression.

Nesbitt H, Byrne NM, Williams SN, Ming L, Worthington J, Errington RJ, Patterson LH, Smith PJ, McKeown SR, McKenna DJ. Nesbitt H, et al. Among authors: worthington j. Clin Cancer Res. 2017 Apr 1;23(7):1797-1808. doi: 10.1158/1078-0432.CCR-16-1361. Epub 2016 Oct 3. Clin Cancer Res. 2017. PMID: 27697998

5

The unidirectional hypoxia-activated prodrug OCT1002 inhibits growth and vascular development in castrate-resistant prostate tumors.

Nesbitt H, Worthington J, Errington RJ, Patterson LH, Smith PJ, McKeown SR, McKenna DJ. Nesbitt H, et al. Among authors: worthington j. Prostate. 2017 Nov;77(15):1539-1547. doi: 10.1002/pros.23434. Epub 2017 Sep 24. Prostate. 2017. PMID: 28944496 Free article.

6

Androgen deprivation in LNCaP prostate tumour xenografts induces vascular changes and hypoxic stress, resulting in promotion of epithelial-to-mesenchymal transition.

Byrne NM, Nesbitt H, Ming L, McKeown SR, Worthington J, McKenna DJ. Byrne NM, et al. Among authors: worthington j. Br J Cancer. 2016 Mar 15;114(6):659-68. doi: 10.1038/bjc.2016.29. Epub 2016 Mar 8. Br J Cancer. 2016. PMID: 26954717 Free PMC article.

7

Androgen deprivation results in time-dependent hypoxia in LNCaP prostate tumours: informed scheduling of the bioreductive drug AQ4N improves treatment response.

Ming L, Byrne NM, Camac SN, Mitchell CA, Ward C, Waugh DJ, McKeown SR, Worthington J. Ming L, et al. Among authors: worthington j. Int J Cancer. 2013 Mar 15;132(6):1323-32. doi: 10.1002/ijc.27796. Epub 2012 Nov 23. Int J Cancer. 2013. PMID: 22915157

8

Bicalutamide-induced hypoxia potentiates RUNX2-mediated Bcl-2 expression resulting in apoptosis resistance.

Browne G, Nesbitt H, Ming L, Stein GS, Lian JB, McKeown SR, Worthington J. Browne G, et al. Among authors: worthington j. Br J Cancer. 2012 Nov 6;107(10):1714-21. doi: 10.1038/bjc.2012.455. Epub 2012 Oct 16. Br J Cancer. 2012. PMID: 23073173 Free PMC article.

9

FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism.

Valentine A, O'Rourke M, Yakkundi A, Worthington J, Hookham M, Bicknell R, McCarthy HO, McClelland K, McCallum L, Dyer H, McKeen H, Waugh DJ, Roberts J, McGregor J, Cotton G, James I, Harrison T, Hirst DG, Robson T. Valentine A, et al. Among authors: worthington j. Clin Cancer Res. 2011 Mar 1;17(5):1044-56. doi: 10.1158/1078-0432.CCR-10-2241. Epub 2011 Mar 1. Clin Cancer Res. 2011. PMID: 21364036 Free PMC article.

10

Transcriptional regulation of inducible nitric oxide synthase gene therapy: targeting early stage and advanced prostate cancer.

Coulter JA, Page NL, Worthington J, Robson T, Hirst DG, McCarthy HO. Coulter JA, et al. Among authors: worthington j. J Gene Med. 2010 Sep;12(9):755-65. doi: 10.1002/jgm.1495. J Gene Med. 2010. PMID: 20821746

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

746 results

Search Page

Filters